Cases & Deals

  • Home
  • Practices
  • Celgene files Hatch-Waxman suit against Mylan over Focalin XR® patents

Share

Celgene files Hatch-Waxman suit against Mylan over Focalin XR® patents

March 2011

Client(s) Celgene Corporation

Jones Day represented Celgene Corporation in a Hatch-Waxman patent infringement action against Mylan Pharmaceuticals concerning a generic version of Celgene’s branded drug Focalin XR®. This matter concluded through a settlement on mutually agreeable terms.

Celgene Corporation et al. v. Mylan Pharmaceuticals, Inc., Civil Action No. 2-11-cv-01882 (D.N.J.) (Judge Arleo)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.